We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Arch Pharmalabs received a Form 483 from the FDA listing numerous problems including water quality, documentation and computer system issues. Read More
Morton Grove Pharmaceuticals, a subsidiary of Wockhardt, received a warning letter from the FDA listing GMP compliance issues at its Illinois facility, including insufficient investigations into product instability. Read More
Two senior Democratic congressmen met with President Donald Trump and discussed a bill granting Medicare the ability to negotiate drug prices, which they plan to introduce in the House within the next two weeks. Read More